It has been shown that asymptomatic obese adolescents can demonstrate abnormal regional
myocardial contraction, with preserved global cardiac function. Metformin has been shown to
decrease cardiovascular mortality in patients with type 2 diabetes and insulin resistance,
but the mechanism of cardiovascular protection is unknown.
The purpose of this study is to evaluate the reversibility of subclinical cardiovascular
abnormalities in obese adolescents with insulin resistance after a six-month course of
Metformin. The investigators hypothesized that the beneficial effects of Metformin will be
progressive and sustained after six months of therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development